Comparison of Earnings and Investment Value: Bristol Myers Squibb vs. Novo Nordisk
NVO Novo Nordisk ADR
$38.64 +1.20%
View chart & analysis → - 1Bristol Myers Squibb recorded $48.2 billion in revenue for fiscal year 2025.
- 2Novo Nordisk revenue for fiscal year 2025 was approximately $46.3 billion, up about 6.4% from the previous year.
- 3Novo Nordisk is a better buying option at the current time.
So what's the key point?
Bristol Myers Squibb and Novo Nordisk reported revenues of $48.2 billion and $46.3 billion, respectively. This means that buying Novo Nordisk is currently a better choice.
Source Nasdaq +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.